The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Ole Jakob Storebø; Erlend Faltinsen; Morris Zwi; Erik Simonsen; Christian Gluud

doi:10.1002/cpt.1149

The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Ole Jakob Storebø^*, Erlend Faltinsen, Morris Zwi, Erik Simonsen, Christian Gluud

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › Research › peer-review

Abstract

Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.

Original language	English
Journal	Clinical Pharmacology and Therapeutics
Volume	104
Issue number	4
Pages (from-to)	606-609
ISSN	0009-9236
DOIs	https://doi.org/10.1002/cpt.1149
Publication status	Published - Oct 2018

Documents & Links

10.1002/cpt.1149

Cite this

@article{a4b7816eb4904c2b94e5e3531559e9e9,

title = "The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder",

abstract = "Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.",

author = "Storeb{\o}, {Ole Jakob} and Erlend Faltinsen and Morris Zwi and Erik Simonsen and Christian Gluud",

year = "2018",

month = oct,

doi = "10.1002/cpt.1149",

language = "English",

volume = "104",

pages = "606--609",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley",

number = "4",

}

The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. / Storebø, Ole Jakob ; Faltinsen, Erlend; Zwi, Morris et al.

In: Clinical Pharmacology and Therapeutics, Vol. 104, No. 4, 10.2018, p. 606-609.

Research output: Contribution to journal › Comment/debate › Research › peer-review

TY - JOUR

T1 - The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

AU - Storebø, Ole Jakob

AU - Faltinsen, Erlend

AU - Zwi, Morris

AU - Simonsen, Erik

AU - Gluud, Christian

PY - 2018/10

Y1 - 2018/10

N2 - Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.

AB - Much remains unclear about the benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Between 2012 and 2018, we conducted two Cochrane systematic reviews on methylphenidate for ADHD. This article explores the main findings in relation to evidence-based practice and our current understanding of ADHD.

U2 - 10.1002/cpt.1149

DO - 10.1002/cpt.1149

M3 - Comment/debate

C2 - 30006934

AN - SCOPUS:85050946131

SN - 0009-9236

VL - 104

SP - 606

EP - 609

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 4

ER -

The Jury Is Still Out on the Benefits and Harms of Methylphenidate for Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Abstract

Documents & Links

Fingerprint

Cite this